Pattern and Rate of Cognitive Decline in Cerebral Small Vessel Disease: A Prospective Study.
Zeestraten, Eva A
Barrick, Thomas R
Morris, Robin G
Public Library of Science (PLoS)
MetadataShow full item record
Lawrence, A., Brookes, R., Zeestraten, E. A., Barrick, T. R., Morris, R. G., & Markus, H. (2015). Pattern and Rate of Cognitive Decline in Cerebral Small Vessel Disease: A Prospective Study.. PLoS One, 10 (e0135523) https://doi.org/10.1371/journal.pone.0135523
OBJECTIVES: Cognitive impairment, predominantly affecting processing speed and executive function, is an important consequence of cerebral small vessel disease (SVD). To date, few longitudinal studies of cognition in SVD have been conducted. We determined the pattern and rate of cognitive decline in SVD and used the results to determine sample size calculations for clinical trials of interventions reducing cognitive decline. METHODS: 121 patients with MRI confirmed lacunar stroke and leukoaraiosis were enrolled into the prospective St George's Cognition And Neuroimaging in Stroke (SCANS) study. Patients attended one baseline and three annual cognitive assessments providing 36 month follow-up data. Neuropsychological assessment comprised a battery of tests assessing working memory, long-term (episodic) memory, processing speed and executive function. We calculated annualized change in cognition for the 98 patients who completed at least two time-points. RESULTS: Task performance was heterogeneous, but significant cognitive decline was found for the executive function index (p<0.007). Working memory and processing speed decreased numerically, but not significantly. The executive function composite score would require the smallest samples sizes for a treatment trial with an aim of halting decline, but this would still require over 2,000 patients per arm to detect a 30% difference with power of 0.8 over a three year follow-up. CONCLUSIONS: The pattern of cognitive decline seen in SVD over three years is consistent with the pattern of impairments at baseline. Rates of decline were slow and sample sizes would need to be large for clinical trials aimed at halting decline beyond initial diagnosis using cognitive scores as an outcome measure. This emphasizes the importance of more sensitive surrogate markers in this disease.
This work was supported by the Wellcome Trust [grant number 081589] and Alzheimer's Research UK [grant number ARUK-PG2013-2].
External DOI: https://doi.org/10.1371/journal.pone.0135523
This record's URL: https://www.repository.cam.ac.uk/handle/1810/249096
Creative Commons Attribution 4.0
Licence URL: http://creativecommons.org/licenses/by/4.0/